EMERYVILLE, Calif.--(BUSINESS WIRE)--Sept. 13, 2006--Omicia, Inc., a privately held company specializing in personalized medicine based on genomic insights, announced today that it has been awarded a $788,517 Small Business Innovation Research (SBIR) Phase II grant from the National Human Genome Research Institute of the National Institutes of Health (NIH). The goal of the funded project is to refine the novel disease marker genome annotation system successfully prototyped by the company during Phase I of this grant.
